Literature DB >> 21136142

Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Philip Chi Lip Kwok1, Amolnat Tunsirikongkon, William Glover, Hak-Kim Chan.   

Abstract

PURPOSE: To produce and examine the aerosol performance of protein nano-matrix particles with different surface roughness.
METHODS: Aqueous lysozyme solutions were poured into isopropanol during high-shear mixing to produce nanoparticles by precipitation. The size of the nanoparticles was varied by adjusting the precipitation conditions. The resultant suspensions were spray-dried to obtain micron-sized aggregates (nano-matrices). Smooth particles were made by spray-drying a lysozyme solution. The aggregate size distribution, surface roughness, and cohesion were evaluated. The aerosol performance was assessed by dispersing 10 mg of powder from a Rotahaler(®) at 60 L/min or an Aerolizer® at 100 L/min into a Next Generation Impactor, followed by chemical assay (n=3).
RESULTS: The median volume diameter and span of the nano-matrix particles were 1.0-1.2 μm and 1.5-1.6, respectively, which were comparable to those of the smooth particles. Surface roughness increased with the size of the primary nanoparticles. The nano-matrix particles were significantly less cohesive than the smooth particles. The fine particle fraction increased linearly with increasing surface roughness and decreasing cohesion.
CONCLUSIONS: Nano-matrix particles with controlled surface architecture were successfully produced by spray-drying nanosuspensions. Aerosol performance was enhanced with increasing surface roughness due to the reduction in cohesion forces.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21136142     DOI: 10.1007/s11095-010-0332-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Can low-dose combination products for inhalation be formulated in single crystalline particles?

Authors:  Michiko Kumon; Philip Chi Lip Kwok; Handoko Adi; Desmond Heng; Hak-Kim Chan
Journal:  Eur J Pharm Sci       Date:  2010-02-19       Impact factor: 4.384

2.  Effervescent dry powder for respiratory drug delivery.

Authors:  Leticia Ely; Wilson Roa; Warren H Finlay; Raimar Löbenberg
Journal:  Eur J Pharm Biopharm       Date:  2006-11-07       Impact factor: 5.571

3.  Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery.

Authors:  Kunn Hadinoto; Kewu Zhu; Reginald B H Tan
Journal:  Int J Pharm       Date:  2007-03-30       Impact factor: 5.875

4.  Micro-particle corrugation, adhesion and inhalation aerosol efficiency.

Authors:  Santoso Adi; Handoko Adi; Patricia Tang; Daniela Traini; Hak-Kim Chan; Paul M Young
Journal:  Eur J Pharm Sci       Date:  2008-06-08       Impact factor: 4.384

5.  Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles.

Authors:  Shirzad Azarmi; Raimar Lobenberg; Wilson H Roa; Shusheng Tai; W H Finlay
Journal:  Drug Dev Ind Pharm       Date:  2008-09       Impact factor: 3.225

6.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  Handoko Adi; Paul M Young; Hak-Kim Chan; Helen Agus; Daniela Traini
Journal:  Eur J Pharm Sci       Date:  2010-04-03       Impact factor: 4.384

7.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

8.  Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation.

Authors:  Tingting Hu; Herbert Chiou; Hak-Kim Chan; Jian-Feng Chen; Jimmy Yun
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

9.  Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy.

Authors:  Carl Plumley; Eric M Gorman; Nashwa El-Gendy; Connor R Bybee; Eric J Munson; Cory Berkland
Journal:  Int J Pharm       Date:  2008-10-25       Impact factor: 5.875

10.  Feasibility of preparing nanodrugs by high-gravity reactive precipitation.

Authors:  Jian-Feng Chen; Min-Yi Zhou; Lei Shao; Yu-Yong Wang; Jimmy Yun; Nora Y K Chew; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2004-01-09       Impact factor: 5.875

View more
  10 in total

1.  Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying.

Authors:  Suzanne M D'Addio; John Gar Yan Chan; Philip Chi Lip Kwok; Bryan R Benson; Robert K Prud'homme; Hak-Kim Chan
Journal:  Pharm Res       Date:  2013-07-27       Impact factor: 4.200

Review 2.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

3.  Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded plga microparticles via spray-drying.

Authors:  Feng Wan; Adam Bohr; Morten Jonas Maltesen; Simon Bjerregaard; Camilla Foged; Jukka Rantanen; Mingshi Yang
Journal:  Pharm Res       Date:  2012-12-11       Impact factor: 4.200

Review 4.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

5.  NanoXCT: a novel technique to probe the internal architecture of pharmaceutical particles.

Authors:  Jennifer Wong; Dexter D'Sa; Matthew Foley; John Gar Yan Chan; Hak-Kim Chan
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

Review 6.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

7.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

8.  Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin.

Authors:  Vaibhav Pathak; Heejun Park; Dmitry Zemlyanov; Sonal V Bhujbal; Maizbha Uddin Ahmed; Mohammad A K Azad; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2022-08-02       Impact factor: 4.580

9.  Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Authors:  Wenbo Wang; Qi Tony Zhou; Si-Ping Sun; John A Denman; Thomas R Gengenbach; Nicolas Barraud; Scott A Rice; Jian Li; Mingshi Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

10.  Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.

Authors:  Hideyuki Sato; Hiroki Suzuki; Keisuke Yakushiji; Jennifer Wong; Yoshiki Seto; Robert K Prud'homme; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-05-25       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.